Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Liver Cancer

TheraSphere for Inoperable Liver Cancer (20111617)
A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patient with Unresectable Hepatocellular Carcinoma (HCC)
Status Conditions Phase Study ID
Recruiting Gastrointestinal Cancer; Liver Cancer; Solid Tumors Phase III 20111617
NCT01556490
Summary

The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.


Investigator
William Harris
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Unresectable advanced HCC not amenable to curative procedures, with planned standard-of-care sorafenib therapy.
  • Other eligibility criteria may apply.
Exclusions (conditions that would prevent participation in this study)
  • Main portal vein thrombosis
  • Other exclusion criteria may apply
Last Updated
September 24, 2013
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.